Idenix Wins $2.5B Verdict In Gilead Hep C Drug Patent Fight
A federal jury took less than two hours Thursday to award Idenix Pharmaceuticals LLC a $2.54 billion royalty share of Gilead Sciences Inc.'s profits from two blockbuster hepatitis C drugs, after...To view the full article, register now.
Already a subscriber? Click here to view full article